Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in BRAF Mutant Melanoma
NCT01726738Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2013
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Started Apr 2013; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01726738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726738.